|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/24/23 Bioxytran, Inc. 8-K:8,9 8/21/23 11:212K M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 38K 2: EX-99.1 Miscellaneous Exhibit HTML 11K 6: R1 Cover HTML 45K 9: XML IDEA XML File -- Filing Summary XML 11K 7: XML XBRL Instance -- form8-k_htm XML 14K 8: EXCEL IDEA Workbook of Financial Report Info XLSX 8K 4: EX-101.LAB XBRL Labels -- bixt-20230821_lab XML 96K 5: EX-101.PRE XBRL Presentations -- bixt-20230821_pre XML 64K 3: EX-101.SCH XBRL Schema -- bixt-20230821 XSD 12K 10: JSON XBRL Instance as JSON Data -- MetaLinks 25± 34K 11: ZIP XBRL Zipped Folder -- 0001493152-23-030051-xbrl Zip 19K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i August 21, 2023
(Exact Name if Business Issuer as specified in its Charter)
| i Nevada | i 001-35027 | i 26-2797630 | ||
(State or other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| i Common Stock, par value $0.001 | i BIXT | OTCPK |
Item 8.01 Other Events.
On August 21, 2023, Bioxytran (the “Company”) has through the U.S. Food and Drug Administration (FDA) received permission in form of an investigational new drug application (IND) under the provisions of section 505(i) of the Federal Food, Drug, and Cosmetic Act, to conduct clinical trial(s) with ProLectin-M the registration IND, No. 153742, by stating “We have completed the review of your submission and have concluded that the clinical trial(s) may be initiated”.
In connection of with the above approval the Company issued on August 24, 2023 a press-release over Globe Newswire, under the title:
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit | ||
| Number | Description | |
| 99.1 | Press-release - Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials, dated August 24, 2023. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| By: | /s/ David Platt | |
| Name: | Dr. David Platt | |
| Title: | President and Chief Executive Officer | |
Dated: August 24, 2023 | ||
| 3 |
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/24/23 | None on these Dates | ||
| For Period end: | 8/21/23 | |||
| List all Filings | ||||